Navigation Links
Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
Date:11/1/2007

SHENZHEN, China, Nov. 1 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence, today announced the appointment of Dr. Jixun Lin as independent director. Dr. Lin replaces Andrew Wolff on the company's board of directors.

"We are delighted to welcome Dr. Lin to our board," said Xu Hang, Mindray's chairman and co-chief executive officer. "Dr. Lin is a leader in the global medical device industry and we are confident that his experience and expertise will be of great benefit to Mindray as we continue to expand into new markets around the world."

"We are very thankful for Mr. Wolff's service on our board. We appreciate his valuable contributions since his appointment and for his willingness to serve on our board after our IPO," added Mr. Xu. Andrew Wolff, managing director of Goldman Sachs, served as Mindray's independent director since February 2006.

Dr. Jixun Lin is founder and chief executive officer of ACON Laboratories Inc., a worldwide leading manufacturer of high-quality rapid diagnostic test products. Dr. Lin founded ACON Laboratories Inc. in 1995 and serves on the company's board of directors. He also serves on the board of directors for ACEA BioSciences Inc., a company providing innovative cell-based assay systems for basic life science research and drug discovery. Mr. Lin received his Ph.D. in microbiology and immunology from the Medical University of South Carolina and a Bachelor of Medicine from Zhejiang Medical University.

Mindray's board now consists of three Mindray officers, Xu Hang (chairman and co-chief executive officer), Li Xiting (p
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), ... royalty revenue from sales of Thalomid® during the ... $3.3 million. In addition, the Company anticipates ... for fiscal 2009. The difference in estimated ... be reflected in the fourth quarter financial results. ...
(Date:12/11/2009)... December 10, 2009 miRagen Therapeutics, Inc., a ... developing innovative microRNA-based therapeutics for cardiovascular and muscle ... that microRNA-206 (miR-206) plays a crucial role in ... Lou Gehrig,s disease) and in neuromuscular synaptic regeneration ... December 11 issue of the journal Science ...
(Date:12/11/2009)... HILL, MA (12/11/2009) Boston College researchers have observed ... the first time and successfully harvested the elusive charges ... improved solar power efficiency, the authors report in the ... , When light is captured in solar cells, it ... But in order to snare these charges, the electrons ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... American Academy of Pediatrics National Conference & ... ... Pa., Oct. 29 Tengion,Inc., a leader in regenerative medicine, announced ... American Academy of,Pediatrics (AAP) National Conference and Exhibition demonstrate the ability,of ...
... SAN MARCOS, Calif., Oct. 29 Cliniqa ... diagnostic products, is pleased to,announce the acquisition ... "Raichem" (San Diego, CA), a wholly owned ... is a manufacturer of clinical,diagnostic products focusing ...
... Repair Discussed at American Society of Plastic Surgeons ... ... the debut of NBC,s,"Bionic Woman," the notion of a bionic person ... getting closer to reality,as reconstructive plastic surgeons perform quality-of-life-enhancing,peripheral nerve surgeries ...
Other Biology Technology:Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2Creating the Bionic Woman: Making Nerves Spring Back to Life 2Creating the Bionic Woman: Making Nerves Spring Back to Life 3
(Date:12/11/2009)... professor of anthropology at the University of Arizona, has ... understand how violence shapes the health of those eking ... and her colleagues, research," Documenting the health consequences of ... A conceptual framework," is currently published in a special ... collaboration with the British medical journal the Lancet ...
(Date:12/11/2009)... edition of Springer,s classic reference and textbook Vogel and ... McKusick Leadership Award. The prize, which recognizes Professor Motulsky,s ... presented to him at the 59th Annual Meeting of ... 2009 in Honolulu, Hawaii. , Motulsky is Professor Emeritus ... Washington in Seattle. One of the founding giants of ...
(Date:12/11/2009)... lost a moderate amount of weight by eating less ... study at Washington University School of Medicine in St. ... in the Dec. 15, 2009, issue of the ... that weight loss led to improvement in four key ... in the study participants included decreased thickness of heart ...
Breaking Biology News(10 mins):UA-led study grapples with health effects of low-intensity warfare 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3From the glass to the brain in 6 minutes 8835 1From the glass to the brain in 6 minutes 8835 2Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 1Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 2Finding Raises Hope for Treating ALS 48916 1Finding Raises Hope for Treating ALS 48916 2
... the Biomedical Engineering Society (BMES) will launch a ... (CMBE) in March 2008. Springer is already ... Biomedical Engineering. , Cellular and Molecular Bioengineering ... of cellular and molecular bioengineering, thus advancing this ...
... A consortium of researchers led by the Genome Sequencing Center ... the completion of a draft sequence of the corn genome. ... partnership with the U.S. Department of Agriculture (USDA) and the ... to sequence the corn genome. The goal of the project ...
... Dr. Peter Glynn, a professor at the University of ... been selected to receive the 2007-2008 Provosts Award for ... pursuits, and provides the recipient with a cash award ... time Glynn, who received the award when it was ...
Other Biology News:Springer expands publishing partnership with the Biomedical Engineering Society 2All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3UM coral scientist Peter Glynn wins award for scholarly activity 2
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
Request Info...
... new Thermo Electron RapidStak provides valuable walk-away ... a unique buffer nest technology for parallel ... RapidStak provides fast, reliable automation for any ... walk-away confidence. The RapidStak can be set-up ...
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
Biology Products: